Is Hologic, Inc. (HOLX) a Buy, Sell, or Hold?
NASDAQ : HOLX
Hologic, Inc.
$76.01 USD
$0.0 (0.0%)
- Volume
- 101.96M
- Average Volume
- 4.49M
- Market Capitalization
- $16.97B
- P/E Ratio
- 31.28
- Dividend Yield
- 0.00%
- Price Target
- $78.50
- Year High
- $76.07
- Year Low
- $51.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.04
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Paul Malenchini |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Current Symbol | HOLX |
| CUSIP | 436440101 |
| CIK | 0000859737 |
| Web | https://www.hologic.com |
| Phone | 508 263 2900 |
| Currency | USD |
| Employees | 7063 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.48 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.04 |
| Quick Ratio | 3.32 |
| Cash Ratio | 2.28 |
Sales & Book Value
| Annual Sales | $4.1B |
| Price / Sales | 4.11 |
| Cash Flow | 4.45 |
| Price / Cash Flow | 16.98 |
| Price / Book | 3.25 |
Price Target and Rating
| Average Stock Price Forecast | $78.50 |
| High Stock Price Forecast | $95.00 |
| Low Stock Price Forecast | $33.00 |
| Forecast Upside/Downside | -3.17% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 42 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $2.49 |
| Trailing P/E Ratio | 31.28 |
| PEG Ratio | -1.33 |
| P/E Growth | -1.33 |
| Net Income | $565.7M |
| Net Margin | 13.18% |
| Pretax Margin | 16.08% |
| Return on Equity | 11.01% |
| Return on Assets | 5.92% |
Financials Score
| AltmanZ Score | 4.24 |
| Piotroski Score | 7.00 |
| Working Capital | 2.89B |
| Total Assets | 9.18B |
| Ebit | 761.8M |
| Market Cap | 16.97B |
| Total Liabilities | 3.94B |
Poll Results
About Hologic, Inc. (NASDAQ:HOLX) Stock
Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for d ... etecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Blackstone, TPG seek over $4 billion for Hologic's surgical unit, FT says
2026-07-09 01:22:03
Private equity groups Blackstone and TPG are seeking more than $4 billion for medical technology firm Hologic's surgical unit, the Financial Times reported on Thursday, citing people familiar with the matter.
Hologic's New Sustainability Report Marks 40 Years of Impact
2026-06-17 09:00:00
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women's health, today released its 2025 Sustainability Report. The new report coincides with Hologic's 40th anniversary and underscores how the company's longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help.
Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology
2026-06-16 13:00:00
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens' latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, F.
2026-05-11 08:00:00
BOSTON--(BUSINESS WIRE)--OM1 helped power a 650,000-patient real-world evidence study supporting FDA approval of Hologic's Aptima HPV Assay for cervical cancer screening.
New Evidence Backs Hologic's AI-Powered Mammography Technology for Detecting Challenging Cancers
2026-04-20 08:05:00
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #WomensHealth--Research presented at the Society of Breast Imaging (SBI) Symposium backs Hologic AI-powered mammography technology for detecting challenging cancers.
Frequently Asked Questions
-
What is the current Hologic, Inc. (HOLX) stock price?
-
Hologic, Inc.(NASDAQ:HOLX) stock price is $76.01 in the last trading session. During the trading session, HOLX stock reached the peak price of $76.07 while $51.9 was the lowest point it dropped to. The percentage change in HOLX stock occurred in the recent session was 0.0% while the dollar amount for the price change in HOLX stock was $0.0.
-
HOLX's industry and sector of operation?
-
The NASDAQ listed HOLX is part of Medical - Instruments & Supplies industry that operates in the broader Healthcare sector.
-
Who are the executives of HOLX?
-
Jennifer Schneiders | President of Diagnostic Solutions
Benjamin Cohn | Vice President & Corporate Controller
Mark Horvath | President of Breast & Skeletal Health Solutions
Mark Irving | Vice President & Corporate Secretary
Paul Malenchini | Chief Information Officer -
How many employees does HOLX have?
-
Number of HOLX employees currently stands at 7063. HOLX operates from 250 Campus Drive, Marlborough, MA 01752, US.
-
Link for HOLX official website?
-
Official Website of HOLX is: https://www.hologic.com
-
How do I contact HOLX?
-
HOLX could be contacted at phone #508 263 2900 and can also be accessed through its website. HOLX operates from 250 Campus Drive, Marlborough, MA 01752, US.
-
How many shares of HOLX are traded daily?
-
The average number of HOLX shares traded daily for last 3 months was 4.49M.
-
What is the market cap of HOLX currently?
-
The market value of HOLX currently stands at $16.97B with its latest stock price at $76.01